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OBJECTIVE—The nitric oxide/cGMP/cGMP-dependent protein
kinase type I (cGKI) signaling pathway regulates cell functions
that play a pivotal role in the pathogenesis of type 2 diabetes.
However, the impact of a dysfunction of this pathway for glucose
metabolism in vivo is unknown.
RESEARCH DESIGN AND METHODS—The expression of
cGKI in tissues relevant to insulin action was analyzed by immu-
nohistochemistry. The metabolic consequences of a genetic de-
letion of cGKI were studied in mice that express cGKI selectively
in smooth muscle but not in other cell types (cGKI-SM mice).
RESULTS—In wild-type mice, cGKI protein was detected in
hepatic stellate cells, but not in hepatocytes, skeletal muscle, fat
cells, or pancreatic b-cells. Compared with control animals,
cGKI-SM mice had higher energy expenditure in the light phase
associated with lower body weight and fat mass and increased
insulin sensitivity. Mutant mice also showed higher fasting glu-
cose levels, whereas insulin levels and intraperitoneal glucose
tolerance test results were similar to those in control animals.
Interleukin (IL)-6 signaling was strongly activated in the liver of
cGKI-SM mice as demonstrated by increased levels of IL-6,
phospho-signal transducer and activator of transcription 3
(Tyr 705), suppressor of cytokine signaling-3, and serum amyloid
A2. Insulin-stimulated tyrosine phosphorylation of the insulin re-
ceptor in the liver was impaired in cGKI-SM mice. The fraction of
Mac-2–positive macrophages in the liver was signiﬁcantly higher
in cGKI-SM mice than in control mice. In contrast with cGKI-SM
mice, conditional knockout mice lacking cGKI only in the ner-
vous system were normal with respect to body weight, energy
expenditure, fasting glucose, IL-6, and insulin action in the liver.
CONCLUSIONS—Genetic deletion of cGKI in non-neuronal cells
results in a complex metabolic phenotype, including liver inﬂam-
mation and fasting hyperglycemia. Loss of cGKI in hepatic stellate
cells may affect liver metabolism via a paracrine mechanism that
involves enhanced macrophage inﬁltration and IL-6 signaling.
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T
he nitric oxide (NO)/cGMP pathway modulates
cell functions in tissues that play a pivotal role
in the pathogenesis of type 2 diabetes (1,2).
One important effector of cGMP is the serine/
threonine kinase cGMP-dependent protein kinase type I
(cGKI) (3,4). cGKI exists in two isoforms, cGKIa and
cGKIb, which are transcribed from the prkg1 gene and
differ only in their N-terminal region (;100 residues). Both
isoforms are widely distributed in eukaryotes and regulate
important functions of the cardiovascular and nervous
system (5–7). However, it is not well understood whether
cGMP/cGKI signaling does affect insulin action in periph-
eral tissues or the brain. Although a modulation of b-cell
apoptosis via cGMP is well accepted (8), the role of NO
and cGMP in the stimulation of insulin secretion is con-
troversially discussed (1,2). The involvement of cGKI as
a potential cGMP effector in these processes and its im-
pact on insulin-sensitive tissues like liver and skeletal
muscle are not clear. Miyashita et al. (9) recently reported
the metabolic characterization of a cGKI transgenic mouse
line. The overexpression of cGKI attenuated diet-induced
obesity and insulin resistance. Moreover, cGKI transgenic
mice were lean and showed increased insulin sensitivity.
However, the consequences of a genetic deletion of the
endogenous cGKI for metabolic regulation and inﬂamma-
tion have not been investigated yet.
In the current study, a potential interaction between the
cGMP/cGKI and the insulin signaling pathway was ana-
lyzed in mice that express cGKI selectively in smooth
muscle to obtain a viable phenotype but not in other cell
types (cGKI-SM mice). In addition to a detailed in vivo
characterization of metabolic parameters, mice were in-
jected with human insulin, insulin receptor (IR) phos-
phorylation was monitored in liver and skeletal muscle,
and the inﬂammatory status on deletion of cGKI was an-
alyzed. Our data suggest that cGKI action is crucial for an
adequate liver metabolism, because a loss of this kinase
results in a metabolic phenotype that is associated with
liver inﬂammation and fasting hyperglycemia.
RESEARCH DESIGN AND METHODS
Experimental animals. The generation of cGKI smooth muscle rescue (cGKI-
SM) mice has been described (10). cGKI-SM mice are deﬁcient for endogenous
cGKI (cGKI
L-/L-) and express the cGKIa or the cGKIb isoform under the
control of the smooth muscle-speciﬁcS M 2 2 a promoter (SM-Ia or SM-Ib res-
cue, respectively). Six- to nine-month-old male SM-Ia rescue or SM-Ib rescue





+/2) were compared with litter-matched control mice that expressed
both endogenous cGKI and the smooth muscle rescue transgene (genotype:
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+/2, collectively referred to as “control” in
the text). Because we could not detect any difference between SM-Ia and SM-
Ib rescue mice in terms of glucose homeostasis, we use the denotation “cGKI-
SM” with regard to both groups. The speciﬁc function of cGKI in the nervous
system was studied in 5- to 12-month-old male neuron-speciﬁc knockout mice
(cGKI-BKO mice) on a C57BL/6 genetic background (genotype: cGKI
L-/L2;Nes-
Cre
tg/0) generated via Cre/loxP recombination by crossing a loxP-ﬂanked cGKI
mouse line with Nestin-Cre mice as described (11). They were compared with
litter-matched control mice (genotype: cGKI
+/L2;Nes-Cre
tg/0). Mice were kept
on a 12-h/12-h light/dark cycle (lights on at 6:00 A.M.) and had access to
a regular chow ad libitum. All procedures were conducted according to the
guidelines of laboratory animal care and were approved by the local govern-
mental commission for animal research.
Immunohistochemistry and Western blot analysis. For immunohisto-
chemistry, animals were deeply anesthetized and perfused with 10% phosphate-
buffered formalin. Tissues were dissected and postﬁxed for 2 h in PBS
containing 2% formaldehyde and 0.2% glutaraldehyde, embedded in parafﬁn,
and cut at 10 mm. Sections were stained with the rabbit polyclonal cGKI
common (DH) antibody (1:1,500) (12), a rabbit polyclonal cellular retinol
binding protein (CRBP)-I antibody (1:200, sc-30106, Santa Cruz Biotechnology,
Santa Cruz, CA), or a rat monoclonal Mac-2 antibody (1:200, CL8942AP,
Cedarlane, Ontario, Canada). For detection of primary antibodies, the avidin-
biotin method with 3,3` diaminobenzidine tetrahydrochloride or Vector Blue
substrate as a chromogen was used (Vector Laboratories, Burlingame, CA).
To control for the speciﬁcity of cGKI immunostainings, tissues derived from
3- to 6-week-old mice with a global deletion of cGKI (cGKI
L-/L-)( 1 3 )w e r eu s e d .
To determine the fraction of CRBP-I or Mac-2–positive cells, nuclei were stained
by incubation of the sections in PBS containing 1 mg/mL Hoechst No. 33258
(Sigma, München, Germany) for 10 min and counted at 1003 magniﬁcation.
Western blot analysis of tissue lysates was done with antibodies against
phospho-Akt (Ser473), phospho-signal transducer and activator of transcrip-
tion 3 (STAT3) (Tyr705), and GAPDH (9271, 9131, and 2118, respectively, Cell
Signaling Technology, Beverly, MA) against phosphoenolpyruvate carboxy-
kinase (PEPCK) (sc-32879, Santa Cruz, Heidelberg, Germany) and suppressor
of cytokine signaling (SOCS)-3 (L210, Cell Signaling Technology). Signals were
visualized with an enhanced chemiluminescence system (Amersham Bio-
sciences, Buckinghamshire, U.K.). For the analysis of PEPCK and glucose-6-
phosphatase, mice were fasted for 16 h and then refed for 6 h.
Analysis of body fat. Intraabdominal fat pads were dissected, and their wet
weightwasdetermined.Magneticresonanceimaginganalysisoffatvolumewas
done in anesthetized mice on a 3-T whole-body magnetic resonance system
(Magnetom Trio, Siemens Healthcare, Erlangen, Germany) applying a T1-
weighted fast spin-echo technique. Mice were placed in a prone position in the
wrist coil of the system. Images were recorded with an in-plane spatial reso-
lution of 0.25 mm and a slice thickness of 2 mm. Postprocessing was done as
described (14).
Liver tissue was ﬁxed in 4% paraformaldehyde in PBS for the histologic
detection of liver fat. Hematoxylin–eosin staining of parafﬁn liver sections was
carried out for analysis of fat content by visual inspection of vesicles.
To determine the hepatic triglyceride content, livers were homogenized
in PBS containing 1% Triton X-100 using a TissueLyser (QIAGEN Sciences,
Germantown, MD). Triglycerides of liver homogenates were quantiﬁed using
the ADVIA 1650 clinical chemistry analyzer (Siemens Healthcare Diagnostics,
Eschborn, Germany).
Measurement of food intake, locomotor activity, and energy expenditure.
Mice were habituated to the test cages for 2 days before trials, and the mea-
surement period lasted 5–6 days. Food intake was recorded with an automated
drinking and feeding monitor system (TSE Systems GmbH, Bad Homburg,
Germany), consisting of Macrolon type III cages equipped with baskets con-
nected to weight sensors. The baskets contained diet pellets and were freely
accessible to the mice. Locomotor activity was recorded with an automated
infrared motion sensor attached to the Macrolon type III cage lid (TSE Systems
GmbH). The sensor monitors the activity of one mouse by sensing the body-heat
image. The software records the total counts during a measuring time interval.
Thereby, the data provide a relative measure of the duration and intensity of the
activity of the mice.
Total energy expenditure (TEE) was measured by indirect calorimetry at
22°C for 24 h with an open circuitry calorimetry system (TSE, Bad Homburg,
Germany) as described previously (15). Before recoding the rate of oxygen
consumption (VO2) and the rate of carbon dioxide production (VCO2), mice
were allowed to adapt to the Macrolon type II cage and to the system for
2 days. The airtight respiratory cages were measured with a ﬂow rate of ;0.38
L/min. VO2 and VCO2 were recorded for 1.5 min in 16-min intervals for each
animal, so that three or four data points were obtained every other hour. TEE
(kcal 3 h
21) was calculated with the equation TEE = 16.17 3 VO2 +5 . 0 33
VCO2 2 5.98 3 N, where N is excreted nitrogen and was assumed to
be (0.1 g 3 d
21). Metabolic body mass-speciﬁcT E Ew a sc a l c u l a t e db y
dividing TEE (kcal 3 h
21)b yb o d yw e i g h t
0.75 of the animal and expressed
as (kcal 3 h
21 3 kg
21).
Analysis of blood samples. Glucose levels were sampled from tail bleeds
using a Glucometer Elite (Bayer, Elkhart, IN). Serum insulin and fasting serum
adiponectin were determined by a radioimmunoassay (Linco Research, St.
Charles, MO), and interleukin (IL)-6 concentrations were measured by the
Quantikine Immunoassay (R&D Systems, Minneapolis, MN). Mouse inﬂam-
matory cytokines were screened by using a Multi-Analyte ELISArray Kit
(MEM-004A, SABiosciences, Frederick, MD). Nonesteriﬁed fatty acids
(NEFAs) were measured in the EDTA-plasma collected after decapitation.
NEFA concentrations were detected using an enzymatic method (WAKO
Chemicals, Neuss, Germany) on the automated clinical chemistry analyzer
ADVIA 1800 (Siemens Healthcare Diagnostics).
Analysis of glucose homeostasis and insulin sensitivity. For the glucose
tolerance test, mice were fasted overnight and 2 g/kg body wt a-D-glucose
was injected intraperitoneally. To determine insulin sensitivity, mice received
0.75 units/kg body wt insulin intraperitoneally (Actrapid, Novo Nordisk,
Denmark). To measure glucose-stimulated insulin release, mice were injected
after an overnight fast with 3 g/kg body wt a-D-glucose.
In vivo insulin stimulation and IR phosphorylation. After an overnight fast,
anesthetized mice were injected into the inferior vena cava with 2 units of
human insulin. After 7 min, liver and skeletal muscle tissues were dissected and
lysed at 4°C in 20 mmol/L Tris (pH 7,4) containing 2 mmol/L EDTA, 137 mmol/L
NaCl, 1% NP-40, 10% glycerol, 12 mmol/L b-glycerol phosphate, 1 mmol/L
phenylmethylsulfonyl ﬂuoride, and 10 mg/mL leupeptin and aprotinin. Homo-
genates were incubated for 30 min on ice and then clariﬁed by centrifugation
at 12,000g for 20 min at 4°C. Supernatants (500 mg of total protein) were
immunoprecipitated with antibodies directed against the carboxy terminus of
the IR (KKNGRILTLPRSNPS; a gift from R. Lammers, University of Tübingen,
Germany). Immunocomplexes were then resolved by SDS-PAGE and im-
munoblotted with antiphosphotyrosine antibody (PY20; Santa Cruz Bio-
technology, Santa Cruz, CA). Signals were visualized with an enhanced
chemiluminescence system (Amersham Biosciences, Buckinghamshire, U.K.),
and densitometric analysis was performed with software from Herolab GmbH
(Wiesloch, Germany).
Gene expression analysis. For mRNA measurements, tissues were frozen in
liquid nitrogen. Total RNA was isolated with QIAzol lysis reagent (QIAGEN
Sciences, Germantown, MD).The RNA was cleaned up with RNeasy Mini Kit
(QIAGEN GmbH, Hilden, Germany), treated with RNase-free DNase I, and
transcribed into cDNA using the ﬁrst-strand cDNA kit from Roche Diagnostics
FIG. 1. Immunohistochemical analysis of cGKI expression in the liver of
WT, global cGKI KO, and cGKI-SM mice. A: Liver sections were stained
with an antibody against cGKI. B: Immunohistochemical single and
double stainings of WT liver for cGKI (upper left panel in brown; all
right panels in blue), CRBP-I (middle panels in brown), and Mac-2
(lower panels in brown). Original magniﬁcations were 403 (A) and
1003 (B). For each genotype, at least four mice were analyzed. Pho-
tomicrographs are representative of one to three stained sections per
mouse. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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dye on a high-speed thermal cycler with integrated microvolume ﬂuorometer
(Roche Diagnostics). Primers were obtained from Invitrogen (Karlsruhe,
Germany). Primer sequences can be provided on request. Measurements were
performed in duplicate. RNA content was normalized to b-actin RNA and is
given in relative expression.
Statistical analysis. Data are expressed as mean 6 SEM, and the numbers of
independent experiments or mice are indicated in Figs. 1–8. For statistical
analysis, the groups were compared using the unpaired Student t test, if not
stated otherwise. The level of signiﬁcance adopted was P , 0.05 (*P , 0.05,
**P , 0.01, ***P , 0.001, or n.s., not signiﬁcant). The statistical software
package JMP 7.0 (SAS Institute Inc., Cary, NC) was used.
RESULTS
Expression of cGKI in insulin-sensitive tissues. Pre-
vious work has shown that the cGKI is strongly expressed
in several brain regions that also contain high concen-
trations of the IR, such as the hypothalamus, cerebellum,
and hippocampus (16,17). However, the presence of cGKI
in peripheral insulin-sensitive tissues has not been in-
vestigated in detail. Thus, the expression pattern of cGKI
was determined in insulin-sensitive tissues of wild-type
mice. By immunohistochemical staining, the cGKI protein
was not detected in fat cells of white or brown adipose
tissue or in skeletal muscle, pancreatic b-cells, or kidney
epithelial cells (data not shown). In liver sections, hep-
atocytes were clearly negative for cGKI, but a fraction of
non-hepatocytes was strongly immunopositive (Fig. 1A).
Notably, these signals were speciﬁc for cGKI because they
were not observed in liver sections of cGKI knockout
mice. Moreover, the cGKI signals were also absent in the
liver of cGKI-SM mice. The latter ﬁnding suggested that the
cGKI-positive liver cells are not smooth muscle cells and
that the cGKI-SM mouse model can be used to study the
effect of cGKI deletion in these cells. To characterize the
cGKI-positive cells in the liver, sections were stained with
antibodies against CRBP-I, a marker for hepatic stellate
cells (18), and Mac-2, which is expressed in liver macro-
phages (19). These analyses indicated that cGKI expres-
sion in the liver is conﬁned to CRBP-I–positive hepatic
stellate cells but not to Mac-2–positive macrophages
(Fig. 1B).
To study the metabolic effects of cGKI deletion, con-
ventional knockout mice are not useful because most of
them die before 6 weeks of age as the result of smooth
FIG. 2. Body weight and fat distribution in cGKI-SM (open bars) and control (black bars) mice that were fed a chow diet. A: Body weight of cGKI-
SM (n=16) and control (n=12) mice. B: Dissected fat pad weight in cGKI-SM and control mice (n=11 per group). C: Magnetic resonance imaging
analysis of visceral and subcutaneous fat deposits: total adipose tissue (D) and lean body mass (E)( n=6 mice per group). F: Liver triacylglycerol
content (n=3–6 mice per group). G: Hematoxylin–eosin staining of liver sections. Images are representative of eight stained sections per group
(n=8 mice per group). H: NEFAs in plasma of cGKI-SM and control mice (n=11 mice per group). CTR, control; TAG, triacylglycerol; TAT, total
adipose tissue. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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two conditional cGKI-deﬁcient mouse models were used:
cGKI smooth muscle rescue mice that express cGKI se-
lectively in smooth muscle but not in other cell types
(cGKI-SM mice) (10) and neuron-speciﬁc knockout mice
lacking cGKI in the brain (cGKI-BKO mice) (11). In con-
trast with cGKI null mutants, cGKI-SM mice and cGKI-BKO
mice have an almost normal life span (10,11,20).
cGKI-SM mice exhibit reduced adipose tissue, liver
fat, and NEFAs. The impact of cGKI ablation on energy
metabolism was examined in cGKI-SM mice and litter-
matched control mice that were fed a standard diet.
Compared with controls, cGKI-SM mice displayed lower
body weight (Fig. 2A) that was associated with a signiﬁ-
cantly decreased fat pad weight (Fig. 2B). As measured by
magnetic resonance imaging, cGKI-SM mice had less total
adipose tissue (Fig. 2C and D), whereas their lean body
mass was similar to that of control mice (Fig. 2E). In line
with their lean phenotype, cGKI-SM mice had a lower he-
patic triacylglycerol content (Fig. 2F) associated with
a decrease in the size and number of liver fat droplets (Fig.
2G). Moreover, cGKI-SM mice had less circulating NEFAs
in their plasma compared with controls (Fig. 2H).
cGKI-SM mice show higher energy expenditure in the
light phase. cGKI-SM mice appeared normal with respect
to food intake (Fig. 3A) and general locomotor activity
(Fig. 3B), both during the light and dark phases. In addi-
tion, we determined energy expenditure of cGKI-SM and
control mice over a 24-h period. Although no difference
could be detected in the dark phase, cGKI-SM mice dis-
played signiﬁcantly elevated energy expenditure in the
light phase compared with control mice (Fig. 3C).
Elevated fasting blood glucose levels despite improved
insulin sensitivity and unaltered glucose tolerance and
insulin levels in cGKI-SM mice. Although there was no
difference in blood glucose levels in the fed state, fasting
blood glucose levels were signiﬁcantly increased in cGKI-
SM mice compared with control mice (Fig. 4A and B). In
a glucose tolerance test, no difference in blood glucose
levels was detectable between cGKI-SM and control mice
(Fig. 4C). The glucose disappearance rate in an insulin tol-
erance test was higher in cGKI-SM than in control mice
(Fig. 4D). After intraperitoneal administration of a high dose
of glucose, no difference in glucose-stimulated insulin re-
lease was detectable between cGKI-SM and control mice
(Fig. 4E). Taken together, cGKI-SM mice displayed un-
altered glucose tolerance and normal basal and glucose-
stimulated insulin release. However, these mouse mutants
showed improved insulin sensitivity and increased fasting
glucose levels.
Insulin action is not affected in muscle but impaired
in the liver of cGKI-SM mice. In vivo, insulin action was
assessed after intravenous insulin application. In skeletal
muscle, intravenous injection of insulin led to a slightly
stronger increase in tyrosine phosphorylation of the IR in
cGKI-SM mice than in control mice, but this difference did
not reach statistical signiﬁcance (Fig. 5A and B). In the
liver of cGKI-SM mice, basal and insulin-induced tyrosine
phosphorylation of the IR was signiﬁcantly decreased (Fig.
5C and D). Moreover, liver tissue of cGKI-SM mice dis-
played reduced Akt phosphorylation at Ser473 on insulin
stimulation (Fig. 5C and D). These ﬁndings favored the
idea that cGKI-SM mice show normal insulin action in
skeletal muscle but insulin resistance in the liver. Indeed,
expression of PEPCK, which catalyzes a rate-limiting step
of gluconeogenesis, was signiﬁcantly increased in the liver
of cGKI-SM mice after fasting and refeeding (Fig. 5E).
However, the reduced IR phosphorylation in the liver
of cGKI-SM mice did not result in signiﬁcant changes
of hepatic glycogen content or expression of glucose-6-
phosphatase mRNA (Supplementary Fig. 1A and B).
In hepatic insulin resistance, liver-speciﬁc fetuin-A can
be upregulated, leading to low-grade inﬂammation and
hypoadiponectinemia (21). Indeed, fetuin-A mRNA was
clearly elevated in the liver of cGKI-SM mice (Fig. 5F),
whereas circulating adiponectin levels were lower (Fig. 5G).
The IL-6 signaling cascade is strongly activated in the
liver of cGKI-SM mice. In parallel to the impaired insulin
action in the liver, a marked increase of IL-6 mRNA was
observed in liver tissue of cGKI-SM mice (Fig. 6A) asso-
ciated with signiﬁcantly elevated circulating IL-6 levels
FIG. 3. Food intake (A), general locomotor activity (B), and total energy
expenditure (C) were monitored over 24 h in cGKI-SM mice (open bars
and symbols, n=10) and control mice (black bars and symbols, n=6) as
described in RESEARCH DESIGN AND METHODS. Animals were analyzed for 5–6
days. Data shown were obtained from day 4 and are representative of the
whole measurement period. Total energy expenditure is expressed in
kilocalories per hour and metabolic body mass (kcal 3 h
21 3 kg
21).
During the light phase, the cGKI-SM mice showed signiﬁcantly higher
energy expenditure than control mice (P < 0.001, two-way ANOVA).
CTR, control.
S.Z. LUTZ AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1569(Fig. 6B). Of note, elevated IL-6 mRNA expression seemed
to be restricted to the liver because skeletal muscle, white
adipose tissue, and spleen of cGKI-SM mice showed no
signiﬁcant alterations (Fig. 6A). Furthermore, gene expres-
sion analysis of tumor necrosis factor-a (Supplementary
Fig. 1C), another proinﬂammatory protein, revealed no
upregulation in the liver of cGKI-SM mice, and other
proinﬂammatory cytokines (IL-2, IL-4, IL-10, IL-12, IL-17A,
interferon-g) were undetectable in the serum of cGKI-SM
mice (data not shown). These results, together with the
previous ﬁnding that the spleens of cGKI-SM mice do not
show altered levels of T cells, B cells, and cytokines (22),
indicated that the cGKI-SM mice studied did not have sys-
temic inﬂammation.
Because cGKI-SM mice showed elevated IL-6 levels, we
monitored the activity of the IL-6 signaling pathway in the
liver of mutant and control mice. Several studies have
reported enhanced hepatic STAT3 activation due to IL-6
action (23–25), so we ﬁrst analyzed the phosphorylation
status of the IL-6 mediator STAT3 and then the expression
of IL-6–regulated genes. In line with an activation of the
IL-6 signaling pathway, phosphorylation of hepatic STAT3
at tyrosine 705, which is known to be phosphorylated on
IL-6 stimulation (26), was stronger in cGKI-SM mice than
in control mice (Fig. 6C). An important effector of IL-6 is
the SOCS-3. It has been shown that IL-6 induces SOCS-3
expression in hepatocytes leading to inhibition of the in-
sulin signaling cascade (27). Indeed, SOCS-3 mRNA levels
were increased approximately ﬁvefold in liver tissue of
cGKI-SM mice compared with controls (Fig. 6D). The
mRNA level of serum amyloid A2, another IL-6/STAT3–
regulated gene (28), was ;11-fold higher in the liver of
cGKI-SM mice than in controls (Fig. 6E). Taken together,
these data indicated that cGKI-SM mice display an acti-
vated IL-6 signaling pathway in the liver.
cGKI in the brain does not interact with hepatic
insulin signaling and energy metabolism. To dissect
whether the described phenotypes are related to cGKI in
the brain, we compared glucose metabolism, as well as
insulin and IL-6 signaling of conditional cGKI-BKO mice,
which lack cGKI in the brain, with controls. cGKI-BKO
mice displayed normal fasting blood glucose levels (Fig. 7A),
glucose tolerance (Fig. 7B), and insulin tolerance (Fig. 7C).
In contrast with cGKI-SM mice, basal and insulin-induced IR
phosphorylation in the liver (Fig. 7D), serum IL-6 (Fig. 7E),
and hepatic SOCS-3 mRNA and protein levels (Fig. 7F)
were not altered. Moreover, cGKI-BKO mice had a normal
body weight (Fig. 7G), locomotor activity (Fig. 7H), and
energy expenditure (Fig. 7I). These results suggested that
the cGMP/cGKI pathway in the brain does not interfere
with insulin action in the liver and energy metabolism.
Increased macrophage inﬁltration in the liver of
cGKI-SM mice. To further analyze the mechanism of
liver inﬂammation and impaired hepatic insulin signaling in
cGKI-SM mice, the cellular makeup of their livers was
compared with control mice. As shown in Fig. 8A, the rel-
ative amount of CRBP-I–positive hepatic stellate cells,
which coexpress cGKI in wild-type mice (Fig. 1B), was not
altered in the absence of cGKI. However, the fraction of
Mac-2–positive macrophages was signiﬁcantly elevated in
the liver of cGKI-SM mice (Fig. 8B). Because cGKI is not
expressed in Mac-2–positive liver macrophages of wild-
type mice (Fig. 1B), these results suggested that cGKI in
hepatic stellate cells enhances macrophage inﬁltration via
FIG. 4. Glucose homeostasis and insulin sensitivity in cGKI-SM (open bars and symbols) and control (black bars and symbols) mice. Blood glucose
concentrations were measured in tail blood of mice fed ad libitum (A) and mice fasted overnight (B)( n=7–15 mice per group). C: Glucose
tolerance tests were performed in overnight fasted mice after intraperitoneal loading with 2 g a-D-glucose per kg body wt. Tail blood samples were
taken at the indicated time points, and glucose was determined (n=7–8 mice per group). D: Insulin tolerance tests were performed in fed mice
after intraperitoneal loading with 0.75 units of human insulin per kg body wt. Tail blood samples were taken at the indicated time points, and
glucose was determined (n=7–8 mice per group). E: Glucose-stimulated insulin release. Mice fasted overnight were injected intraperitoneally with
a-D-glucose (3 g/kg body wt), and serum insulin concentrations were measured at the indicated time points (n=7 mice per group). CTR, control.
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cytokines including IL-6 that result in increased liver in-
ﬂammation and impaired insulin action.
DISCUSSION
Our data suggest that deletion of the cGKI in hepatic
stellate cells results in enhanced recruitment of IL-6–
secreting macrophages to the liver, thereby inhibiting insulin
signaling. Extensive work has shown that IR signaling can
be attenuated at the level of IR substrate (Irs) proteins by
several serine kinases that are activated by obesity and
inﬂammation, such as JNK, IKK, S6K1, and PKCs (29–32).
NO/cGMP signaling has also been implicated in the mod-
ulation of glucose homeostasis, and the serine/threonine
protein kinase cGKI is an important effector of this path-
way (1–4). cGKI is highly expressed in smooth muscle
cells, where it plays a crucial role in relaxation (10,20,33)
and in several brain regions (16). This study elucidated
the role of cGKI in glucose metabolism in vivo and focused
FIG. 5. Insulin signaling in skeletal muscle (A and B) and liver (C and D) of cGKI-SM (open bars) and control (black bars) mice. Mice received an
intravenous injection of 2 units of human insulin or vehicle. Tyrosine phosphorylation of the IR was detected in immunoprecipitates of the IR (IP:
IR) by immunoblotting with a phospho-tyrosine speciﬁc antibody (IB: p-Tyr; upper blots). The total level of IR was used as a loading control (IB:
IR; lower blots). A: Tyrosine phosphorylation of the IR in skeletal muscle. The shown immunoblot is representative of three independent
experiments. B: Densitometric analysis of the fraction of tyrosine phosphorylated IR in skeletal muscle. Results are given in arbitrary units (AU)
(n=3 mice per group). C: Tyrosine phosphorylation of the IR (upper) and phosphorylation of Akt at Ser473 (lower) in the liver; as loading
controls, IR and GAPDH were used, respectively. The immunoblots shown are representative of three to four independent experiments. D:
Densitometric analysis of the fraction of tyrosine phosphorylated IR (n=3 mice per group) and phospho-Akt (Ser473) (n=5–7 mice) in the liver.
Results are given in AU. E: Western blot analysis of PEPCK expression in the liver after fasting and refeeding. The shown immunoblot is repre-
sentative of one experiment with six control and ﬁve cGKI-SM mice. The results of the densitometric analysis are given in AU. F: Expression
analysis of hepatic fetuin-A mRNA by quantitative RT-PCR (n=4–6 mice per group). G: Fasting serum adiponectin levels (n=11 mice per group).
CTR, control. (A high-quality color representation of this ﬁgure is available in the online issue.)
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action. We report that cGKI-SM mice, which are deﬁcient
for endogenous cGKI in all tissues except smooth muscle,
show a complex metabolic phenotype associated with liver
inﬂammation and fasting hyperglycemia. This phenotype
was not observed in neuron-speciﬁc cGKI knockout mice
demonstrating that it was not due to a defect of cGMP/
cGKI signaling in the brain. It is also unlikely that the
defects reﬂect a role of cGKI in fat cells, skeletal muscle,
pancreatic b-cells, or kidney epithelial cells, because we
were unable to detect cGKI protein in these cell types
in wild-type mice. In the liver, cGKI was undetectable in
hepatocytes, but expressed in CRBP-I–positive stellate cells.
To our knowledge, this is the ﬁr s tr e p o r to fc G K Ie x -
pression in hepatic stellate cells. The cGKI might be a
potential downstream mediator of cGMP signaling in these
cells. Indeed, previous studies have already indicated the
presence of cGMP-generating enzymes in hepatic stellate
cells (34).
The current study shows that cGKI-SM mice have higher
energy expenditure in the light phase than control mice.
The higher metabolic rate could, at least in part, explain
their reduced fat mass and improved whole-body insulin
sensitivity. It is unlikely that these phenotypes are linked
to a defective central regulation, because cGKI-BKO mice
showed normal energy expenditure, body weight, and in-
sulin sensitivity. On the basis of the expression proﬁle of
cGKI, a direct interaction between cGKI and insulin action
in fat cells or skeletal muscle seems unlikely. Moreover,
insulin-stimulated tyrosine phosphorylation of the IR was
not signiﬁcantly altered in skeletal muscle of cGKI mutant
mice. Therefore, we hypothesize that the improved whole-
body insulin sensitivity of cGKI-SM mice is related to their
higher energy expenditure and slightly reduced body
weight and fat content with similar food intake. On the
other hand, cGKI-SM mice had normal basal and glucose-
stimulated insulin levels, and their glucose tolerance was
indistinguishable from that of control mice. These data,
together with the lack of cGKI expression in b-cells of
wild-type mice, indicate that the cGMP/cGKI pathway is
not involved in insulin secretion. This result does not
contradict previous studies that suggested a role of NO or
cGMP in insulin-secreting cells (1,2) because both NO and
cGMP can exert effects independently of cGKI. cGKI-SM
mice displayed profound fasting hyperglycemia but normal
insulin levels. Although recent work suggests an in-
volvement of cGKI in the secretion of glucagon (35), our
expression analyses do not support a direct role of cGKI in
glucagon-secreting a-cells (data not shown). Basal and
insulin-stimulated IR tyrosine phosphorylation was signif-
icantly reduced in the liver of cGKI-SM mice, and in line
with this, insulin-induced Akt phosphorylation at Ser473
was decreased as well. Together with elevated expression
of PEPCK after fasting and refeeding, these ﬁndings in-
dicate impaired hepatic insulin action in cGKI-SM mice.
Chronic inﬂammation is one of the major factors caus-
ing hepatic insulin resistance, and the cytokine IL-6 is
known to play a key role. Elevated IL-6 levels cause he-
patic insulin resistance both in vitro (36,37) and in vivo
(24,38). IL-6–induced insulin resistance is mediated, at
least in part, by tyrosine phosphorylation and activation of
the transcription factor STAT3, resulting in stimulation of
FIG. 6. IL-6 signaling in cGKI-SM (open bars) and control (black bars) mice. A: Expression analysis of IL-6 mRNA in various tissues by quantitative
RT-PCR (n=4–6 mice per group). B: Serum IL-6 concentrations (n=7–8 mice per group). C: Phosphorylation of hepatic STAT3. Liver tissue was
analyzed by immunoblotting with a phospho-STAT3 (Tyr705) antibody. GAPDH was used as a loading control. One representative immunoblot of
three independent experiments with 8–10 mice is shown. Expression analysis of SOCS-3 mRNA (D) and serum amyloid A2 mRNA (E) by quan-
titative RT-PCR (n=4–6 mice per group). CTR, control. WAT, white adipose tissue.
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action via several mechanisms, such as binding to the IR
(39), inhibition of tyrosine phosphorylation of Irs1 and Irs2
(37), or reduction of Irs1 and Irs2 protein levels by stim-
ulation of their proteosome-mediated degradation (40).
Indeed, cGKI-SM mice had signiﬁcantly elevated IL-6 levels
in their liver and circulation. Moreover, the IL-6 signaling
cascade was strongly activated in the liver of cGKI-SM
mice as monitored by enhanced phosphorylation of STAT3
at tyrosine 705 and increased expression of SOCS-3 and
serum amyloid A2. Serum IL-6 levels in the mutant mice
were approximately sixfold higher than those present in
healthy humans but similar to those seen in different states
of chronic inﬂammation (41,42).
It is important to note that IL-6 mRNA was elevated in
the liver of cGKI-SM mice but not in skeletal muscle, white
adipose tissue, and spleen. Thus, the liver might be the
primary source for increased circulating IL-6. In wild-type
mice, cGKI is expressed in hepatic stellate cells but not
in hepatocytes and other liver cells. How could loss of
cGKI in stellate cells lead to increased hepatic IL-6? It is
well known that stellate cells have a remarkable plasticity
FIG. 7. Analysis of neuron-speciﬁc cGKI knockout mice (cGKI-BKO mice, open bars and symbols) and their litter-matched controls (black bars and
symbols). A: Blood glucose concentrations were measured in tail blood of overnight fasted mice (n=5 per group). B: Glucose tolerance tests were
performed in overnight fasted mice as described in RESEARCH DESIGN AND METHODS and in the Fig. 4 legend (n=5–6 mice per group). C: Insulin tol-
erance tests were performed in fed mice after intraperitoneal loading with 0.75 units of human insulin per kg body wt. Tail blood samples were
taken at the indicated time points, and glucose was determined (n=4 mice per group). D: Tyrosine phosphorylation of the IR in the liver was
determined as described in the Fig. 5 legend. Shown are representative immunoblots of three independent experiments. E: Serum IL-6 concen-
trations (n=5 mice per group). F: SOCS-3 mRNA expression in the liver (n=5 mice per group) and protein levels (one representative immunoblot
is shown, n=4). Body weight (G), general locomotor activity (H), and total energy expenditure (I) were monitored over 24 h in cGKI-BKO mice
(n=5) and control mice (n=5) as described in RESEARCH DESIGN AND METHODS and in the Fig. 3 legend. Mice in A–F were 5 months old, and mice in G–I
were 9 to 12 months old. CTR, control. (A high-quality color representation of this ﬁgure is available in the online issue.)
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paracrine interactions with other resident liver cells
(34). In particular, stellate cells secrete and respond to a
number of cytokines, including IL-6. Dysfunction of the
cGMP/cGKI pathway in stellate cells was associated
with a markedly increased fraction of Mac-2–positive
macrophages in the liver, without affecting the number of
stellate cells. Thus, although increased IL-6 secretion by
cGKI-deﬁcient stellate cells cannot be excluded, it is likely
that enhanced macrophage inﬁltration and macrophage-
derived IL-6 play a major role for liver inﬂammation and
insulin resistance in cGKI-SM mice. Stellate cells pro-
duce factors that regulate macrophage accumulation and
growth, such as monocyte chemoattractant protein-1 (34).
Although we could not detect altered expression of mono-
cyte chemoattractant protein-1 mRNA in livers of cGKI-SM
mice (Supplementary Fig. 1D), serum granulocyte colony-
stimulating factor was clearly elevated in these mice, i.e.,
two of two IL-6–positive cGKI-SM mice were positive for
granulocyte colony-stimulating factor (data not shown).
Further experiments are needed to dissect the autocrine/
paracrine mechanisms of this novel hepatic cGMP/cGKI
pathway in more detail.
On the basis of our results, alternative mechanisms
could also contribute to hepatic inﬂammation and im-
paired IR phosphorylation in cGKI-SM mice. The liver
protein fetuin-A acts as a natural inhibitor of the IR
tyrosine kinase (43–45), induces IL-6 expression, and sup-
presses the production of the insulin-sensitizing adipokine,
adiponectin (21,46,47). Indeed, expression of fetuin-A mRNA
was elevated in the liver of cGKI-SM mice, whereas circu-
lating adiponectin levels were signiﬁcantly repressed.
The elevated IL-6 level might not only affect liver me-
tabolism but also contribute to the development of other
phenotypes that are observed in cGKI-SM mice. In addition
to a lipolytic effect of IL-6 in adipose tissues (48), several
studies reported an antiobesity effect of low doses of IL-6
at the level of the brain, leading to increased energy
expenditure and decreased body weight (29). Moreover,
administration of IL-6 to human volunteers induced higher
energy expenditure (49) and elevated fasting blood glu-
cose levels (50). Macrophage-derived IL-6 may also cause
anemia via induction of the iron-regulatory hormone hep-
cidin in hepatocytes (51). Thus, elevated IL-6 in cGKI-SM
mice may, at least in part, be responsible for their in-
creased energy expenditure, lean phenotype, fasting hy-
perglycemia, and anemia (22).
In conclusion, this study provides evidence that the
cGMP/cGKI pathway does not directly interfere with the
insulin signaling cascade in skeletal muscle, b-cells, and
the brain. However, adequate liver metabolism depends on
cGKI action because loss of this protein kinase results in
hepatic inﬂammation. This phenotype might, at least in
part, be caused by increased IL-6 signaling. We propose
that loss of cGKI in hepatic stellate cells stimulates mac-
rophage inﬁltration and activation of the hepatic IL-6/
STAT3/SOCS-3 pathway, which leads to impaired insulin
action and fasting hyperglycemia.
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